Inovio Pharmaceuticals Inc (GBMB.DU)
- Simply Wall St.
Inovio Pharmaceuticals (NASDAQ:INO) adds US$37m to market cap in the past 7 days, though investors from a year ago are still down 69%
Inovio Pharmaceuticals, Inc. ( NASDAQ:INO ) shareholders should be happy to see the share price up 11% in the last...
- Benzinga
Within A Month After Pulling Plug On COVID-19 Booster Study, Inovio Shelves Two More Infectious Disease Programs
Inovio Pharmaceuticals Inc (NASDAQ: INO) has agreed with its collaborator, the Coalition for Epidemic Preparedness Innovations (CEPI), to discontinue the development of product candidates targeting Lassa Fever (INO-4500) and Middle East Respiratory Syndrome (MERS) (INO-4700). Recently, Inovio discontinued its internally funded efforts to develop INO-4800 as a COVID-19 heterologous booster vaccine. The move follows the initial data analyses from studies conducted by Inovio and funded by CEPI. Dr.
- American City Business Journals
Inovio shares fall on discontinuation of development of two more vaccine candidates
Inovio is discontinuing development of its vaccine product candidates targeting Lassa Fever and Middle East Respiratory Syndrome, or MERS, the latest setback for the Montgomery County biotechnology company. Inovio said it agreed with its collaborator, the Coalition for Epidemic Preparedness Innovations (CEPI), to stop work on both experimental products, INO-4500 and INO-4700, following initial analyses of data from studies testing the effectiveness of each.
